Free Trial

Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

Xenon Pharmaceuticals logo
$32.68 +1.26 (+4.01%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$33.40 +0.72 (+2.20%)
As of 07/9/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Xenon Pharmaceuticals Stock (NASDAQ:XENE)

Key Stats

Today's Range
$31.65
$33.51
50-Day Range
$28.49
$38.28
52-Week Range
$26.74
$46.00
Volume
1.26 million shs
Average Volume
636,847 shs
Market Capitalization
$2.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.82
Consensus Rating
Buy

Company Overview

Xenon Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

XENE MarketRank™: 

Xenon Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 419th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Xenon Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Xenon Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($3.10) to ($3.76) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xenon Pharmaceuticals is -10.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xenon Pharmaceuticals is -10.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xenon Pharmaceuticals has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Xenon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    5.09% of the float of Xenon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xenon Pharmaceuticals has recently increased by 9.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Xenon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Xenon Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.09% of the float of Xenon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xenon Pharmaceuticals has recently increased by 9.50%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Xenon Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Xenon Pharmaceuticals this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $91.00 in company stock.

  • Percentage Held by Insiders

    Only 5.52% of the stock of Xenon Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xenon Pharmaceuticals' insider trading history.
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Stock News Headlines

Xenon Appoints CEO Ian Mortimer as Interim CFO
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
Xenon Joins the Russell 3000® and Russell 2000® Indexes
See More Headlines

XENE Stock Analysis - Frequently Asked Questions

Xenon Pharmaceuticals' stock was trading at $39.20 on January 1st, 2025. Since then, XENE shares have decreased by 16.6% and is now trading at $32.68.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings results on Monday, May, 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.07. The biopharmaceutical company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $1.64 million.
Read the conference call transcript
.

Xenon Pharmaceuticals' top institutional shareholders include Harbor Capital Advisors Inc. (0.04%). Insiders that own company stock include Ian Mortimer, Dawn Svoronos, Gary Patou, James R Empfield, Sherrington Robin, Steven Gannon, Simon N Pimstone, Sherry Aulin and Christopher John Kenney.
View institutional ownership trends
.

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Deckers Outdoor (DECK), Adobe (ADBE) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
5/12/2025
Today
7/09/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XENE
CIK
1582313
Employees
210
Year Founded
N/A

Price Target and Rating

High Price Target
$67.00
Low Price Target
$47.00
Potential Upside/Downside
+67.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$234.33 million
Pretax Margin
-3,406.93%

Debt

Sales & Book Value

Annual Sales
$7.50 million
Price / Cash Flow
N/A
Book Value
$9.90 per share
Price / Book
3.30

Miscellaneous

Free Float
72,498,000
Market Cap
$2.51 billion
Optionable
Optionable
Beta
1.10

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:XENE) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners